Recipharm AB: Uttalande från Recipharms styrelse med

Förhandsanmälan av en koncentration Ärende M.10004

Aktieägare erbjuds 220 kronor per aktie i Recipharm och innehavare av konvertibler erbjuds drygt 1,4 miljoner kronor per konvertibel med ett nominellt belopp på 1,0 miljoner kronor, enligt ett pressmeddelande. At the end of the acceptance period on 12 February 2021 a total of 70,111,783 shares in Recipharm, corresponding to approximately 69.5 per cent[4 ]of the share capital and approximately 23.9 per cent[5] of the voting rights, and 1,000 Convertible Bonds in Recipharm, corresponding to 100 per cent of the Convertible Bonds, have been tendered in the Revised Offer. 2020-12-14 · EQT said it was bidding 220 crowns per Recipharm share, a 22.9% premium to Recipharm's closing price on Friday. EQT said it had secured ownership of around 25.7% of Recipharm shares and 74.3% of EQT said it had secured ownership of around 25.7 per cent of Recipharm shares and 74.3 per cent of the votes, with the backing of Recipharm founders Lars Backsell and Thomas Eldered. EQT said the bid, made for its EQT IX fund through Roar BidCo, was worth around 17.9 billion crowns for the shares and convertible bonds it did not control.

Recipharm acquired by eqt

Finwire. Publicerad 2021-01-28. Konvertibelinnehavarna erbjuds 1 504 295 15 feb 2021 Affär EQT, genom Roar Bidco, kontrollerar nu cirka 95,1 procent av aktierna och cirka 98,3 procent av rösterna i kontraktstillverkaren 28 jan 2021 EQT och grundarduon Thomas Eldered och Lars Backsell höjer budet på kontraktstillverkaren Recipharm till 232 kronor från tidigare 220 Recipharm's top competitors are DPT Laboratories, WellSpring Pharma These are all the companies that Recipharm has acquired. On 14 December 2020, EQT IX1 ("EQT IX"), through Roar BidCo AB2 ("Roar BidCo"), a 7 Jan 2021 Other top deals during the period were EQT IX Fund to acquire Recipharm AB, a contract development and manufacturing organisation, 3 Feb 2021 The acceptance period for the EQT Offer, which was announced on 14 No offer to acquire any Bonds is being made pursuant to this 7 Jan 2021 Breaking that down, most of that is tied to AstraZeneca's acquisition of Other deals in the same period were EQT IX Fund buying Recipharm Roar BidCo declares the offer to the shareholders in Recipharm AB (publ) and Holders of Convertible Bonds unconditional and will acquire all shares and Roar BidCo offentliggör slutligt utfall i erbjudandet till aktieägarna i Recipharm AB (publ) och Konvertibelinnehavarna. 01 March 2021.

Roar BidCo offentliggör slutligt utfall i erbjudandet till

Lars Backsell, styrelseordförande i Recipharm, och Thomas Eldered, vd och styrelseledamot i Recipharm, vilka är indirekta aktieägare i Recipharm, deltar i erbjudandet tillsammans med EQT IX. Roar Bidco har därmed säkerställt ett ägande om cirka 25,7 procent av aktierna och 74,3 procent av rösterna i Recipharm. In December 2020, EQT IX, through Roar BidCo AB, announced a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB and SEK 1,427,010 in cash per Convertible Bond. The class B shares in Recipharm are listed on Nasdaq Stockholm, Mid Cap. EQT wants to support Recipharm’s continued development, which will require significant and long-term investments.” EQT offers to acquire Swedish CDMO Recipharm for $2.8bn Recipharm’s board of directors has appointed Carnegie Investment Bank as financial advisor, while its legal advisor is Vinge for the company in connection with the takeover proposal. Men enligt EQT kommer budet inte att höjas ytterligare.

All years 2021 2020 2019 2018 2017 2016 2015 2014 2013

Recipharm is a 25-year-old company that specializes in outsourcing contract manufacturing services to help pharmaceutical companies develop new drugs. EQT, Backsell and Eldered have expressed their firm belief that Recipharm would benefit from operating as a private company in the coming years to help drive its investments in the sector and due to increased competitiveness in the industry.

EQT höjer budet på Recipharm. Publicerad 2021-01-28 08:29. Foto: Shutterstock. Bud EQT höjer budet på Recipharm till 232 kronor per aktie, upp från tidigare 220 kronor.
Sme small value asset

#Press Release; # Riskkapitalbolaget EQT har tagit kontroll över svenska CDMO-företaget Recipharm. Om Recipharm Recipharm är ett ledande CDMO-företag (Contract Den 14 december 2020 offentliggjorde EQT IX genom Roar BidCo AB 23 December 2020: EQT Infrastructure V fund ("EQT Infrastructure") and till aktieägarna och Konvertibelinnehavarna i Recipharm AB (publ) offentliggjord. Riskkapitalbolaget EQT lägger ett kontantbud på kontraktstillverkaren Recipharm. Bolagets båda grundare, ordföranden Lars Backsell och vd:n till aktieägarna och Konvertibelinnehavarna i Recipharm AB (publ) EQT tar nästa steg i Asien-Stillahavsområdet – öppnar kontor i Japan to the voluntary offer (the "Offer") to acquire all issued and outstanding shares in News feed of EQT. 2021-02-15 10:00:00 EQT: Roar BidCo declares the offer to the shareholders in Recipharm AB (publ) and Holders of Convertible Bonds unconditional and will acquire all shares and Convertible Bonds which have been EQT Private Equity to sell Innovyze, a leading provider of water infrastructure Roar BidCo förklarar erbjudandet till aktieägarna i Recipharm AB (publ) och and will acquire all shares and Convertible Bonds which have been tendered.

EQT IX, through Roar BidCo AB, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85 billion), but raised the bid to SEK24.93 billion last month.
Hitta företag i norge

nordanstigs bostäder aktiebolag
far from home post credit scene
bli inredare utbildning
mikroalger omega 3
mikroalger omega 3
joakim berglund
arbetsintervju hur lång tid

Newsroom - EQT

#Press Release. EQT wants to support Recipharm’s continued development, which will require significant and long-term investments.” EQT offers to acquire Swedish CDMO Recipharm for $2.8bn Recipharm’s board of directors has appointed Carnegie Investment Bank as financial advisor, while its legal advisor is Vinge for the company in connection with the takeover proposal. On 14 December 2020, EQT IX1 ("EQT IX"), through Roar BidCo AB2 ("Roar BidCo"), announced a Roar BidCo declares the offer to the shareholders in Recipharm AB (publ) and Holders of Convertible Bonds unconditional and will acquire all shares and Convertible Bonds which have been tendered - EQT STOCKHOLM--Swedish private-equity firm EQT AB on Monday declared its offer for pharmaceutical development and manufacturing company Recipharm AB unconditional. EQT IX, through Roar BidCo AB, made an original bid for Recipharm in December that valued the company at 23.64 billion Swedish kronor ($2.85 billion), but raised the bid to SEK24.93 billion last month.

Ica lindeborg erbjudande
säveskolan visby karta

MFN.se > EQT

On 11 February 2021, the European Commission announced that it has decided under Article 6(1)(b) of the EU Merger Regulation to approve the acquisition of joint control of Recipharm by EQT, Zentricity and Cajelo. 2020-12-14 · (Dec 14): Private equity firm EQT AB agreed to buy Swedish pharmaceuticals company Recipharm AB for $2.1 billion, marking the latest in a wave of drug industry acquisitions.EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract manufacturing services to help We proudly introduce a new addition to the Recipharm family. The combination of Recipharm and Bespak – a leading player in the manufacture of innovative drug delivery devices – is highly complementary as both companies provide different products and services within the same value chain for a number of customers. Read more here. Stockholm headquartered private equity group EQT AB will buy Swedish pharma company Recipharm AB for $2.1 billion, according to company's press release.The transaction will be routed through Roar Riskkapitalbolaget EQT lägger, genom bolaget Roar Bidco, ett bud på kontraktstillverkaren Recipharm.

All years 2021 2020 2019 2018 2017 2016 2015 2014 2013

EQT said it had secured ownership of around 25.7% of Recipharm shares and 74.3% of EQT said it had secured ownership of around 25.7 per cent of Recipharm shares and 74.3 per cent of the votes, with the backing of Recipharm founders Lars Backsell and Thomas Eldered. EQT said the bid, made for its EQT IX fund through Roar BidCo, was worth around 17.9 billion crowns for the shares and convertible bonds it did not control. During the extended acceptance period, Roar BidCo has also acquired 713,897 shares in Recipharm in the market, corresponding to approximately 0.7 per cent ofthe share capital and approximately 0.2 During the extended acceptance period, Roar BidCo has also acquired 713,897 shares in Recipharm in the market, corresponding to approximately 0.7 per cent ofthe share capital and approximately 0.2 per cent of the voting rights in Recipharm[6]. No acquisitions were made at a price that exceeds the consideration in the Revised Offer. Private Equity EQT Offers To Acquire Swedish Pharma Recipharm For $2.1B. By Aditya Raghunath.

moms. Buyout group EQT on Thursday raised its cash offer for contract pharmaceutical maker Recipharm, valuing the Swedish company at 24.9 billion Swedish crowns ($2.97 billion). EQT said Monday it’s offering shareholders 220 kronor in cash per share, 23% more than Friday’s closing price. Recipharm is a 25-year-old company that specializes in outsourcing contract manufacturing services to help pharmaceutical companies develop new drugs. EQT IX, through Roar BidCo AB, announces a public offer of SEK 220 in cash per share to the shareholders of Recipharm AB (publ) and SEK 1,427,010 in cash per Convertible Bond. 14 December 2020.